Skip to main content
Psychiatric Annals, 2010;40(7):325–332
Published Online:https://doi.org/10.3928/00485713-20100701-05Cited by:13
First page image

  • 1.National Collaborating Centre for Mental Health. Core interventions in the treatment of obsessive compulsive disorder and body dysmorphic disorder (a guideline from the National Institute for Health and Clinical Excellence, National Health Service). 2006. Accessed June 28, 2010. www.nice.org.uk/page.aspx?o=289817.

    > Google Scholar
  • 2.Ipser J, Sander C, Stein D. Pharmacotherapy and psychotherapy for body dysmorphic disorder. Cochrane Database Syst Rev. 2009 21(1);CD005332.

    > Google Scholar
  • 3.Phillips KA. Understanding Body Dysmorphic Disorder: An Essential Guide. New York, NY: Oxford University Press; 2009.

    > Google Scholar
  • 4.Phillips KA, Pagano ME, Menard W. Pharmacotherapy for body dysmorphic disorder: treatment received and illness severity. Ann Clin Psychiatry. 2006; 18(4):251–257.10.1080/10401230600948464

    > CrossrefGoogle Scholar
  • 5.Phillips KA, Dwight MM, McElroy SL. Efficacy and safety of fluvoxamine in body dysmorphic disorder. J Clin Psychiatry. 1998; 59(4):165–171.

    > Google Scholar
  • 6.Eisen JL, Phillips KA, Coles ME, Rasmussen SA. Insight in obsessive compulsive disorder and body dysmorphic disorder. Compr Psychiatry. 2004; 45(1):10–15.10.1016/j.comppsych.2003.09.010

    > CrossrefGoogle Scholar
  • 7.Wilhelm S, Phillips KA, Steketee G. Cognitive-Behavioral Therapy for Body Dysmorphic Disorder: A Modular Treatment Manual. New York, NY: Guilford Press, Inc. In press.

    > Google Scholar
  • 8.Miller WR, Rollnick S. Motivational Interviewing: Preparing People to Change Addictive Behavior. New York, NY: Guilford Press; 1991.

    > Google Scholar
  • 9.Phillips KA, Hollander E. Treating body dysmorphic disorder with medication: Evidence, misconceptions, and a suggested approach. Body Image. 2008; 5(1):13–27.10.1016/j.bodyim.2007.12.003

    > CrossrefGoogle Scholar
  • 10.Brady KT, Austin L, Lydiard RB. Body dysmorphic disorder: the relationship to obsessive-compulsive disorder. J Nerv Ment Dis. 1990; 178(8):538–540.

    > Google Scholar
  • 11.Hollander E, Liebowitz MR, Winchel R, Klumker A, Klein DF. Treatment of body-dysmorphic disorder with serotonin reuptake blockers. Am J Psychiatry. 1989; 146(6):768–770.

    > Google Scholar
  • 12.Phillips KA. Body dysmorphic disorder: the distress of imagined ugliness. Am J Psychiatry. 1991; 148(9):1138–1149.

    > Google Scholar
  • 13.Phillips KA, McElroy SL, Keck PE, Pope HG, Hudson JI. Body dysmorphic disorder: 30 cases of imagined ugliness. Am J Psychiatry. 1993; 150(2):302–308.

    > Google Scholar
  • 14.Phillips KA, McElroy SL, Keck PE, Pope HG, Hudson JI. A comparison of delusional and nondelusional body dysmorphic disorder in 100 cases. Psychopharmacol Bull. 1994; 30(2):179–186.

    > Google Scholar
  • 15.Hollander E, Allen A, Kwon J, et al.Clomipramine vs desipramine crossover trial in body dysmorphic disorder: selective efficacy of a serotonin reuptake inhibitor in imagined ugliness. Arch Gen Psychiatry. 1999; 56(11):1033–1039.10.1001/archpsyc.56.11.1033

    > CrossrefGoogle Scholar
  • 16.Phillips KA, Albertini RS, Rasmussen SA. A randomized placebo-controlled trial of fluoxetine in body dysmorphic disorder. Arch Gen Psychiatry. 2002; 59(4):381–388.10.1001/archpsyc.59.4.381

    > CrossrefGoogle Scholar
  • 17.Phillips KA, Rasmussen SA. Change in psychosocial functioning and quality of life of patients with body dysmorphic disorder treated with fluoxetine: a placebo-controlled study. Psychosomatics. 2004; 45(5):438–444.10.1176/appi.psy.45.5.438

    > CrossrefGoogle Scholar
  • 18.Perugi G, Giannotti D, Di Vaio S, Frare F, Saettoni M, Cassano GB. Fluvoxamine in the treatment of body dysmorphic disorder (dysmorphophobia). Int Clin Psychopharmacol. 1996; 11(4):247–254.10.1097/00004850-199612000-00006

    > CrossrefGoogle Scholar
  • 19.Phillips KA. An open-label study of escitalopram in body dysmorphic disorder. Int Clin Psychopharmacol. 2006; 21(3):177–179.10.1097/01.yic.0000194378.65460.ef

    > CrossrefGoogle Scholar
  • 20.Phillips KA, Najar F. An open-label study of citalopram in body dysmorphic disorder. J Clin Psychiatry. 2003; 64(6):715–720.10.4088/JCP.v64n0615

    > CrossrefGoogle Scholar
  • 21.Phillips KA, Siniscalchi JM, McElroy SL. Depression, anxiety, anger, and somatic symptoms in patients with body dysmorphic disorder. Psychiatric Q. 2004; 75(4):309–320.10.1023/B:PSAQ.0000043507.03596.0d

    > CrossrefGoogle Scholar
  • 22.Phillips KA, Kelly MM. Suicidality in a placebo-controlled fluoxetine study of body dysmorphic disorder. Int Clin Psychopharmacol. 2009; 24(1):26–28.10.1097/YIC.0b013e32831db2e9

    > CrossrefGoogle Scholar
  • 23.Veale D, Boocock A, Gournay K, Dryden W. Body dysmorphic disorder: a survey of fifty cases. Br J Psychiatry. 1996; 169(2):196–201.10.1192/bjp.169.2.196

    > CrossrefGoogle Scholar
  • 24.Phillips KA, Coles ME, Menard W, Yen S, Fay C, Weisberg RB. Suicidal ideation and suicide attempts in body dysmorphic disorder. J Clin Psychiatry. 2005; 66(6):717–725.10.4088/JCP.v66n0607

    > CrossrefGoogle Scholar
  • 25.Phillips KA, Menard W. Suicidality in body dysmorphic disorder: a prospective study. Am J Psychiatry. 2006; 163(7):1280–1282.10.1176/appi.ajp.163.7.1280

    > CrossrefGoogle Scholar
  • 26.Phillips KA, Albertini RS, Siniscalchi JM, Khan A, Robinson M. Effectiveness of pharmacotherapy for body dysmorphic disorder: a chart-review study. J Clin Psychiatry. 2001; 62(9):721–727.

    > Google Scholar
  • 27.Albertini RS, Phillips KA, Guevremont D. Body dysmorphic disorder in a young child (letter). J Am Acad Child Adolesc Psychiatry. 1996; 35(11):1425–1426.10.1097/00004583-199611000-00010

    > CrossrefGoogle Scholar
  • 28.El-khatib HE, Dickey T. Sertraline for body dysmorphic disorder. J Am Acad Child Adolesc Psychiatry. 1995; 34(11):1404–1405.10.1097/00004583-199511000-00004

    > CrossrefGoogle Scholar
  • 29.Heimann SW. SSRI for body dysmorphic disorder. J Am Acad Child Adolesc Psychiatry. 1997; 36(7):868.10.1097/00004583-199707000-00004

    > CrossrefGoogle Scholar
  • 30.Sondheimer A. Clomipramine treatment of delusional disorder-somatic type. J Am Acad Child Adolesc Psychiatry. 1988; 27(2):188–192.10.1097/00004583-198803000-00010

    > CrossrefGoogle Scholar
  • 31.Albertini RS, Phillips KA. Thirty-three cases of body dysmorphic disorder in children and adolescents. J Am Acad Child Adolesc Psychiatry. 1999; 38(4):453–459.10.1097/00004583-199904000-00019

    > CrossrefGoogle Scholar
  • 32.Phillips KA, McElroy SL, Dwight MM, Eisen JL, Rasmussen SA. Delusionality and response to open-label fluvoxamine in body dysmorphic disorder. J Clin Psychiatry. 2001; 62(2):87–91.

    > Google Scholar
  • 33.Phillips KA. The Broken Mirror: Understanding and Treating Body Dysmorphic Disorder. (Revised and expanded edition). New York, NY: Oxford University Press; 2005.

    > Google Scholar
  • 34.Phillips KA. Placebo-controlled study of pimozide augmentation of fluoxetine in body dysmorphic disorder. Am J Psychiatry. 2005; 162(2):377–379.10.1176/appi.ajp.162.2.377

    > CrossrefGoogle Scholar
  • 35.Phillips KA. Olanzapine augmentation of fluoxetine in body dysmorphic disorder (letter). Am J Psychiatry. 2005; 162(5):1022–1023.10.1176/appi.ajp.162.5.1022-a

    > CrossrefGoogle Scholar
  • 36.Phillips KA. An open study of buspirone augmentation of serotonin-reuptake inhibitors in body dysmorphic disorder. Psychopharmacol Bull. 1996; 32(1):175–180.

    > Google Scholar
  • 37.Phillips KA, Menard W. A Prospective pilot study of levetiracetam for body dysmorphic disorder. CNS Spectr. 2009; 14(5):252–260.

    > Google Scholar
  • 38.Allen A, Hadley SJ, Kaplan A, et al.An open-label trial of venlafaxine in body dysmorphic disorder. CNS Spectr. 2008; 13(2):138–144.

    > Google Scholar
  • 39.Hollander E, Cohen LJ, Simeon D, Rosen J, deCaria CM, Stein D. Fluvoxamine treatment of body dysmorphic disorder. J Clin Psychopharmacol. 1994; 14(1):75–77.

    > Google Scholar
  • 40.Phillips KA. Pharmacologic treatment of body dysmorphic disorder. Psychopharmacol Bull. 1996; 32(4):597–605.

    > Google Scholar
  • 41.Hay G. Dysmorphophobia. Br J Psychiatry. 1970; 116(533):399–406.10.1192/bjp.116.533.399

    > CrossrefGoogle Scholar
  • 42.Mindus P. Personal communication.

    > Google Scholar
  • 43.Cassem E. Personal communication.

    > Google Scholar
  • 44.Rassmussen S. Personal communication.

    > Google Scholar

We use cookies on this site to enhance your user experience. For a complete overview of all the cookies used, please see our privacy policy.

×